文献速递肥胖与代谢综合征

司美拉诺肽(MC4R激动剂)治疗Bardet-Biedl综合征和Alström综合征的疗效与安全性:多中心、随机、双盲、安慰剂对照、3期试验及开放标签期

Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period.
PubMed 文献 · Lancet Diabetes Endocrinol · 2022-11-07

这项多中心随机双盲安慰剂对照3期试验纳入38例Bardet-Biedl综合征或Alström综合征患者,评估司美拉诺肽对体重的影响。在Bardet-Biedl综合征12岁及以上患者中,32.3%达到52周体重较基线降低至少10%;Alström综合征结果不确定。常见不良事件为皮肤色素沉着和注射部位红斑,无治疗相关严重不良事件。

要点

  • Bardet-Biedl综合征12岁及以上患者中,32.3%经司美拉诺肽治疗52周体重降低≥10%。
  • Alström综合征患者结果不确定。
  • 最常见治疗中出现的不良事件为皮肤色素沉着(61%)和注射部位红斑(48%)。

核心结论

  • 司美拉诺肽可使Bardet-Biedl综合征患者体重显著降低;但在Alström综合征患者中结果不确定。
  • 结果支持使用司美拉诺肽,并为该药获批作为Bardet-Biedl综合征肥胖的首个治疗药物提供了必要证据。

研究设计与样本

  • 多中心、随机、14周双盲、安慰剂对照3期试验,随后52周开放标签期,在美国、加拿大、英国、法国和西班牙的12个中心(医院、诊所和大学)进行。
  • 纳入年龄≥6岁、临床诊断Bardet-Biedl综合征或Alström综合征且肥胖的患者。
  • 患者按1:1随机分配接受皮下司美拉诺肽(最大3.0 mg)每日一次或安慰剂,双盲期14周,随后开放标签司美拉诺肽52周。
  • 主要终点在完整分析集中测量:52周司美拉诺肽治疗后,年龄≥12岁患者体重较基线降低至少10%的比例。
  • 2018年12月10日至2019年11月25日期间,38例患者入组并随机分配至司美拉诺肽组(n=19)或安慰剂组(n=19;每组16例Bardet-Biedl综合征和3例Alström综合征)。

主要发现

  • 主要终点:Bardet-Biedl综合征12岁及以上患者中,32.3%(95% CI 16.7至51.4;p=0.0006)在司美拉诺肽治疗52周后体重较基线降低至少10%。
  • 最常见治疗中出现的不良事件为皮肤色素沉着(23/38,61%)和注射部位红斑(18/38,48%)。
  • 两例患者发生4次严重不良事件(失明、过敏反应和自杀意念);均认为与司美拉诺肽治疗无关。

关键数值与推荐

  • 肥胖定义:6-15岁患者BMI大于同龄同性别第97百分位,≥16岁患者BMI≥30 kg/m2。
  • 主要终点:52周司美拉诺肽治疗后,年龄≥12岁患者体重较基线降低至少10%的比例。

临床怎么用

  • 结果支持使用司美拉诺肽,并为该药获批作为Bardet-Biedl综合征肥胖的首个治疗药物提供了必要证据。

局限性

  • 在Alström综合征患者中结果不确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Impaired cilial signalling in the melanocortin-4 receptor (MC4R) pathway might contribute to obesity in patients with Bardet-Biedl syndrome and Alström syndrome, rare genetic diseases associated with hyperphagia and early-onset severe obesity. We aimed to evaluate the effect of setmelanotide on bodyweight in these patients. METHODS: This multicentre, randomised, 14-week double-blind, placebo-controlled, phase 3 trial followed by a 52-week open-label period, was performed at 12 sites (hospitals, clinics, and universities) in the USA, Canada, the UK, France, and Spain. Patients aged 6 years or older were included if they had a clinical diagnosis of Bardet-Biedl syndrome or Alström syndrome and obesity (defined as BMI >97th percentile for age and sex for those aged 6-15 years and ≥30 kg/m2 for those aged ≥16 years). Patients were randomly assigned (1:1) using a numerical randomisation code to receive up to 3·0 mg of subcutaneous setmelanotide or placebo once per day during the 14-week double-blind period, followed by open-label setmelanotide for 52 weeks. The primary endpoint, measured in the full analysis set, was the proportion of patients aged 12 years or older who reached at least a 10% reduction in bodyweight from baseline after 52 weeks of setmelanotide treatment. This study is registered with ClinicalTrials.gov, NCT03746522. FINDINGS: Between Dec 10, 2018, and Nov 25, 2019, 38 patients were enrolled and randomly assigned to receive setmelanotide (n=19) or placebo (n=19; 16 with Bardet-Biedl syndrome and three with Alström syndrome in each group). In terms of the primary endpoint, 32·3% (95% CI 16·7 to 51·4; p=0·0006) of patients aged 12 years or older with Bardet-Biedl syndrome reached at least a 10% reduction in bodyweight after 52 weeks of setmelanotide. The most commonly reported treatment-emergent adverse events were skin hyperpigmentation (23 [61%] of 38) and injection site erythema (18 [48%]). Two patients had four serious adverse events (blindness, anaphylactic reaction, and suicidal ideation); none were considered related to setmelanotide treatment. INTERPRETATION: Setmelanotide resulted in significant bodyweight reductions in patients with Bardet-Biedl syndrome; however, these results were inconclusive in patients with Alström syndrome. These results support the use of setmelanotide and provided the necessary evidence for approval of this drug as the first treatment for obesity in patients with Bardet-Biedl syndrome. FUNDING: Rhythm Pharmaceuticals.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Haqq AM, Chung WK, Dollfus H, et al. Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period. Lancet Diabetes Endocrinol. 2022. PMID: 36356613. doi:10.1016/S2213-8587(22)00277-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。